HS-10506 + itraconazole

HS-10506 + itraconazole is a drug combination used in clinical pharmacology studies to evaluate the pharmacokinetic interaction between HS-10506, an investigational sedative-hypnotic agent, and itraconazole, a potent CYP3A4 inhibitor. HS-10506 is a small molecule developed by Jiangsu Hansoh Pharmaceutical Co., Ltd. that acts as a positive allosteric modulator of the GABA-A receptor, intended for the treatment of insomnia. Itraconazole is an antifungal medication that also serves as a strong inhibitor of the cytochrome P450 3A4 enzyme. The co-administration of these two agents in a fixed-sequence, self-controlled study allows researchers to determine the extent of CYP3A-mediated metabolism of HS-10506, which is essential for understanding its safety and potential for drug-drug interactions in a clinical setting.

Other names

HS-10506 and itraconazoleHS10506 and itraconazoleHS 10506 and itraconazole